OutbreakWatch
Outbreaks
en

Mpox (monkeypox)

Monkeypox virus (MPXV) · Poxviridae

Strains

  • Clade I (Central African) — more severe
  • Clade Ia
  • Clade Ib (2024 DRC outbreak)
  • Clade II (West African)
  • Clade IIa
  • Clade IIb (2022-2024 global outbreak)

Transmission

  • Direct contact with skin lesions, rash, scabs, or body fluids of an infected person
  • Prolonged close physical contact, including sexual contact
  • Contact with infected animals (zoonotic — rodents, non-human primates)
  • Contact with contaminated materials such as bedding or clothing
  • Respiratory droplets during prolonged face-to-face contact (less common)

Symptoms

Prodromal phase (days 0–5)

  • Fever (38–40 °C / 100.4–104 °F) — often the first sign
  • Intense headache
  • Swollen lymph nodes (lymphadenopathy) — key feature distinguishing mpox from smallpox and chickenpox
  • Back pain and muscle aches (myalgia)
  • Profound fatigue and weakness
  • Chills

Rash phase — clade I classic presentation (1–5 days after fever onset)

  • Rash begins on the face, then spreads centrifugally to trunk and extremities
  • Palms and soles typically affected
  • Lesion progression: macules → papules → vesicles → pustules → scabs over 2–4 weeks
  • All lesions at the same stage simultaneously (synchronous evolution)
  • Lesions are deep-seated, well-circumscribed, and often painful

Rash phase — clade IIb mpox rash symptoms (2022–2024 global outbreak pattern)

  • Fewer lesions, sometimes only 1–5 total
  • Genitoanal and perirectal location predominant
  • Painful proctitis and anal ulcers
  • Rash may appear before or simultaneously with fever
  • Oral and pharyngeal lesions — sore throat, difficulty swallowing

Complications (severe or immunocompromised cases)

  • Secondary bacterial skin infections
  • Pneumonia — especially in immunocompromised individuals and young children
  • Encephalitis (rare)
  • Keratitis or corneal scarring from periocular lesions
  • Sepsis
Incubation
5-21 days (typically 6-13 days)
Mortality rate
Clade I: 1-10%; Clade II: <1% in resource-rich settings
Vaccine
Yes

Treatment

Tecovirimat (TPOXX/ST-246) is approved for orthopoxvirus infections including mpox; brincidofovir and cidofovir are used in severe cases. Most clade II cases are self-limiting and resolve in 2-4 weeks with supportive care (pain management, wound care, hydration).

Vaccine status

JYNNEOS (MVA-BN, Imvamune/Imvanex) is approved for both mpox and smallpox; ACAM2000 is also protective but carries more side-effect risk. Recommended as a 2-dose series for at-risk groups. Pre-1980 smallpox vaccination conferred ~85% cross-protection, now waned.

Endemic regions

  • Democratic Republic of the Congo — clade I, recurrent outbreaks (2024 clade Ib PHEIC)
  • Central Africa (Congo Basin) — clade I reservoir
  • West Africa (Nigeria and neighbours) — clade II reservoir
  • Global (2022-2024) — clade IIb spread to 100+ countries, twice declared a PHEIC by WHO

Frequently asked questions

Compare to other viruses

Sources

Last update Jun 24, 2026 · ⚠ Not medical advice.